Biocartis (Switzerland) a commercial-stage molecular diagnostics company focused on rapid biomarker identification, closed a $100M Series C financing. Participants include Debiopharm Group, Philips, Johnson & Johnson Development Corp, Wellcome Trust, Korys and Valiance.